February 2026
1. ROBERT C, Psimaras D, Choquet S, Bonnefont-Rousselot D, et al
   Early serum S100beta but not neuron-specific enolase reflects baseline CNS vulnerability in ICANS after CD19 CAR T-cell therapy.
   J Neurol. 2026;273:148.
   

   >> Share

   
   January 2026
2. ASIOLI GM, Pondrelli F, Spinardi L, Faccioli L, et al
   Prospective observational study of magnetic resonance imaging in anti-CD19 CAR T-cell-associated neurotoxicity.
   J Neurol. 2026;273:109.
   

   >> Share

   
   April 2025
3. PONDRELLI F, Muccioli L, Mason F, Zenesini C, et al
   EEG as a predictive biomarker of neurotoxicity in anti-CD19 CAR T-cell therapy.
   J Neurol. 2025;272:360.
   

   >> Share

   
   January 2025
4. GARCIA CR, Robertson IJ, Gregory TA, Zahid A, et al
   Differential diagnosis in immune checkpoint inhibitors neurotoxicity.
   J Neurol. 2025;272:116.
   

   >> Share

   
   July 2024
5. MARANO M, Pilotto A, Padovani A, Gupta D, et al
   The chronic use of serotonin norepinephrine reuptake inhibitors facilitates dyskinesia priming in early Parkinson's disease.
   J Neurol. 2024;271:3711-3720.
   

   >> Share

   
   May 2023
6. PENSATO U, Amore G, Muccioli L, Sammali S, et al
   CAR t-cell therapy in BOlogNa-NEUrotoxicity TReatment and Assessment in Lymphoma (CARBON-NEUTRAL): proposed protocol and results from an Italian study.
   J Neurol. 2023;270:2659-2673.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share